Navigation Links
Protox Announces Positive Clinical Data from Prostate Cancer Study

VANCOUVER, British Columbia, July 10, 2007 /CNW/ - Protox Therapeutics Inc. (TSX-V:PRX) today announced positive top-line results from its Phase 1 clinical trial evaluating PRX302 in patients with localized, recurrent prostate cancer following radiation failure. The trial results indicate that PRX302 is safe and well tolerated and shows promising signs of therapeutic activity following a single intra-prostatic treatment.

"The completion of the PRX302 Phase 1 trial is encouraging from two perspectives," said Dr. Scott Coffield, Principal Investigator from the lead site, Scott and White Memorial Hospital. "First, there was therapeutic benefit demonstrated through overall PSA reduction in study patients, as well as a reduction in the number of positive biopsies after treatment. Second, there was no significant adverse side effect profile at the highest dose of PRX302 given to patients in this trial."

"It is heartening to see promising results at this stage of the clinical development program in a patient population which has limited therapeutic options," said Dr. Fahar Merchant, President and Chief Executive Officer of Protox. "These data support our heightened confidence regarding the potential of PRX302 for the treatment of not only prostate cancer, but also BPH, which is currently being evaluated in an ongoing Phase I trial."

This study is intended to examine the safety, tolerability and therapeutic activity of PRX302 in patients with localized recurrent prostate cancer who show signs of disease progression as evidenced by rising levels of PSA (prostate specific antigen) following radiation treatment. Using a well-established, image-guided technique, PRX302 was administered directly into the prostate. A total of 24 patients were treated in this trial. Protox has concluded that despite a 100-fold escalation in dose, the maximum tolerated dose (MTD) was not reached in this study while e
'"/>




Page: 1 2 3 4 5

Related medicine technology :

1. Protox Announces Publication in Journal of the National Cancer Institute Supporting PRX302 as Treatment for Prostatic Diseases
2. Antisoma Announces Further Data From ASA404 Ovarian Cancer Trial
3. Neose Announces Presentation of Positive Preclinical Data on GlycoPEGylated Factor VIIa at the XXI Congress of the International Society on Thrombosis and Haemostasis
4. Biofrontera AG Announces Clinical Study Confirms Excellent Efficacy of BF-200 ALA In Actinic Keratosis
5. YM BioSciences Announces Secondary Efficacy and Safety Findings in Randomized Phase IIB Aerolef Trial
6. BioSante Pharmaceuticals Announces New Findings for Potential Bird Flu Vaccine
7. Portola Pharmaceuticals Announces Positive Data from a Phase II Study of its Factor Xa Inhibitor at the XXI Congress of the International Society on Thrombosis and Haemostasis
8. Manhattan Pharmaceuticals Announces Results of Phase 2a Studies for Oral Oleoyl-estrone
9. AVI BioPharma Partner Cook Medical Announces Completion of Patient Enrollment for APPRAISAL Phase II Clinical Trial for Treatment of Cardiovascular Disease
10. Inspire Announces Webcast of Presentation at C.E. Unterberg, Towbin Emerging Growth Opportunities Conference
11. NexMed Announces Completion of Patient Enrollment in Two Pivotal Phase 3 Studies for Anti-Fungal Product
Post Your Comments:
(Date:1/15/2014)... 2014  In an unprecedented effort to curb the spread ... ambulances and other transport vehicles, an advanced and portable UV ... rescue personnel for the first time. In ... in contact with these deadly pathogens, West Palm ... nation to begin sanitizing the interior surfaces of its ambulance ...
(Date:1/15/2014)... , Jan. 15, 2014 The ... as a Medical Fitness Center by the Medical ... health and fitness centers to achieve their full ... the only certified fitness center in the western ... "The certification means the Cadence Fitness & ...
(Date:1/15/2014)... Jan. 15, 2014  Valeant Pharmaceuticals International, Inc. (NYSE: ... the applicable waiting period under the Hart-Scott-Rodino Antitrust Improvements ... announced tender offer by its indirect wholly-owned subsidiary, Sapphire ... of common stock of Solta Medical, Inc. (NASDAQ: ... per share, net to the seller in cash, without ...
Breaking Medicine Technology:Superbugs No Longer Ride In Rescue Vehicles 2Cadence Fitness & Health Center Certified as Medical Fitness Facility 2Cadence Fitness & Health Center Certified as Medical Fitness Facility 3Valeant Pharmaceuticals Announces Receipt Of Antitrust Clearance For Its Previously Announced Acquisition Of Solta Medical, Inc. 2Valeant Pharmaceuticals Announces Receipt Of Antitrust Clearance For Its Previously Announced Acquisition Of Solta Medical, Inc. 3
... , SWARTZ CREEK, Mich., Nov. 17 Diplomat Specialty ... Bernardino, CA . Diplomat has 6 additional locations in ... contracts with managed care organizations in California will potentially impact ... Managed Care. "Our new San Bernardino location is an important ...
... , SOUTH SAN FRANCISCO, Calif., Nov. 17 ... announced updated clinical data from its randomized, controlled Phase ... cancer (CRC). The updated results indicated that picoplatin, ... and leucovorin in the FOLPI regimen, has comparable efficacy ...
Cached Medicine Technology:Diplomat Specialty Pharmacy Continues to Expand - Opens Location in Southern California 2Poniard Pharmaceuticals Announces Updated Positive Clinical Data from Phase 2 Trial of Picoplatin in Colorectal Cancer and New Phase 1 Cardiac Safety Trial Results 2Poniard Pharmaceuticals Announces Updated Positive Clinical Data from Phase 2 Trial of Picoplatin in Colorectal Cancer and New Phase 1 Cardiac Safety Trial Results 3Poniard Pharmaceuticals Announces Updated Positive Clinical Data from Phase 2 Trial of Picoplatin in Colorectal Cancer and New Phase 1 Cardiac Safety Trial Results 4Poniard Pharmaceuticals Announces Updated Positive Clinical Data from Phase 2 Trial of Picoplatin in Colorectal Cancer and New Phase 1 Cardiac Safety Trial Results 5
(Date:3/7/2014)... PLAINS, NY, March 7, 2014 -- Five researchers seeking ... goal of identifying women at risk of preterm labor ... awarded grant support from the March of Dimes. , ... seeking to understand what role genetic variations, infection, fetal ... triggering preterm labor. They have been awarded 2014 March ...
(Date:3/7/2014)... 80 percent of raw chicken used in hospitals ... a form of antibiotic resistant bacteria called extended-spectrum beta-lactamase ... eliminated the presence of bacteria, poultry meat delivered to ... these dangerous bacteria into the hospital. The study was ... and Hospital Epidemiology , the journal of the Society ...
(Date:3/7/2014)... those men most at risk of prostate cancer rather ... a leading scientist from The University of Manchester - ... at an international conference this week. , Men in ... for prostate cancer once they reach the age of ... biopsy if their PSA level is greater than their ...
(Date:3/6/2014)... from UNC,s Frank Porter Graham Child Development ... Program produces significant positive outcomes for children, ... language skills. FPG,s research on nearly 1,200 ... math, and general knowledge for students enrolled ... "These findings demonstrate compelling evidence for the ...
(Date:3/5/2014)... TALLAHASSEE, Fla. Frequent Facebook users might be sharing ... they also share a greater risk of eating ... State University researchers. , Psychology Professor Pamela K. Keel ... on Facebook was associated with higher levels of disordered ... and "likes" on their status updates and were more ...
Breaking Medicine News(10 mins):Health News:New research seeks to prevent preterm birth with March of Dimes support 2Health News:Hospital food safety measures reduce risk of contaminated hospital food 2Health News:New approach to prostate cancer screening needed 2Health News:Large-scale study shows power of pre-k 2Health News:Large-scale study shows power of pre-k 3Health News:Hungry for 'likes': Frequent Facebook use linked to eating disorder risk, study finds 2
... mammography at six-month intervals can detect breast cancers not identified ... Texas M. D. Anderson Cancer Center will report at the ... MRI is known to be more sensitive in detecting breast ... compared to a 16 - 40 percent accuracy for mammography. ...
... NEW YORK, Dec. 13 New York Blood Center (NYBC),will ... PM, for years,of dedication on behalf of thousands of New ... lives. To date, more than 100,blood drives have been ... York Blood Center. , ...
... Dec. 13 The following is a transcript of President Bush,s weekly ... THE PRESIDENT: Good morning. This week, our country received good ... illicit drug use amongst young people continues to decline -- and that ... Americans renew their health and hope. , , ...
... MyPyramid for Preschoolers, helps parents expand little ones, diet ... News) -- A new federal government food pyramid for ... especially as youngsters are introduced to new kinds of ... interactive Web site (MyPyramid.gov) offers individualized nutrition guidance to ...
... Hissey Kientz, LLP wishes to alert patients of the serious and potentially ... patch. Patients who are directly exposed to the gel inside the patch, ... develop respiratory depression or other serious and potentially fatal side effects. ... ...
... Cut Largest Source of Deadly Diesel Pollution in State , ... The California Air Resources Board today approved two diesel ... diesel pollution in the state and are the first of ... Fund (EDF). The Air Resource Board estimates that the truck ...
Cached Medicine News:Health News:Alternating mammography and MRI may be best for high-risk women 2Health News:NYPD Recruits Recognized for Giving Gift of Life 2Health News:Radio Address by President Bush to the Nation 2Health News:Radio Address by President Bush to the Nation 3Health News:New Food Pyramid Is Aimed at Kids 2Health News:Hissey Kientz, LLP Warns Duragesic Patch Users About Potential Health Risks of Fentanyl Overdose 2Health News:Hissey Kientz, LLP Warns Duragesic Patch Users About Potential Health Risks of Fentanyl Overdose 3Health News:California Rules to Cut Diesel Truck Pollution Called Most Sweeping in U.S. 2
Sub Pectoral Breast Augmentation Wrap...
Bras and Breast Support...
Post-Surgical compression garments...
Our Osteomark® ELISA kits provide a quantitative measurement of cross-linked N-telopeptides of type I collagen (NTx) as an indicator of bone resorption, with higher levels in serum or urine sampl...
Medicine Products: